Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I):



(I)

wherein:

A is absent or is $(CH_2)_2$;

R^1 is $C(O)NR^{10}R^{11}$, $C(O)_2R^{12}$, $NR^{13}C(O)R^{14}$, $NR^{15}C(O)NR^{16}R^{17}$, $NR^{18}C(O)_2R^{19}$, heterocyclyl (for example piperidine, piperazine, pyrrolidine or azetidine), aryl, cycloalkyl or heteroaryl;

R^{10}, R^{13}, R^{15}, R^{16} and R^{18} are hydrogen or C_{1-6} alkyl;

R^{11}, R^{12}, R^{14}, R^{17} and R^{19} are C_{1-8} alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl (optionally substituted by halo), C_{5-6} cycloalkenyl, $S(C_{1-4}$ alkyl), $S(O)(C_{1-4}$ alkyl), $S(O)_2(C_{1-4}$ alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C_{3-7} cycloalkyl (optionally substituted by halo or C_{1-4} alkyl), C_{4-7} cycloalkyl fused to a phenyl ring, C_{5-7} cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, $C(O)(C_{1-6}$ alkyl), $S(O)_k(C_{1-6}$ alkyl), halo or C_{1-4} alkyl); or R^{11}, R^{12}, R^{14} and R^{17} can also be hydrogen;

or R^{10} and R^{11}, and/or R^{16} and R^{17} may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C_{1-6} alkyl, $S(O)_l(C_{1-6}$ alkyl) or $C(O)(C_{1-6}$ alkyl);

R^2 is phenyl, heteroaryl or C_{3-7} cycloalkyl;

R^3 is H or C_{1-4} alkyl;

X is $S(O)_2NR^4R^5$ or $NR^6S(O)_2R^7$;

R^7 is aryl, heteroaryl, C_{1-6} alkyl, C_{3-7} cycloalkyl, heterocyclyl or NR^8R^9 wherein NR^8R^9 can be cyclized to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C_{1-6} alkyl, $S(O)_p(C_{1-6}$ alkyl) or $C(O)(C_{1-6}$ alkyl);

R^4 and R^8 are aryl, heteroaryl, C_{1-6} alkyl (optionally substituted by hydroxy or C_{1-6} alkoxy), C_{3-7} cycloalkyl or heterocyclyl;

R^5, R^6 and R^9 are, independently, hydrogen or C_{1-6} alkyl;

n is 1, 2 or 3;

aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, $OC(O)NR^{20}R^{21}$, $NR^{22}R^{23}$, $NR^{24}C(O)R^{25}$, $NR^{26}C(O)NR^{27}R^{28}$, $S(O)_2NR^{29}R^{30}$, $NR^{31}S(O)_2R^{32}$, $C(O)NR^{33}R^{34}$, CO_2R^{36}, $NR^{37}CO_2R^{38}$, $S(O)_qR^{39}$, $OS(O)_2R^{49}$, C_{1-6} alkyl (optionally mono-substituted by $S(O)_2R^{50}$ or $C(O)NR^{51}R^{52}$), C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenylS(O), phenylS$(O)_2$, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C_{1-4} alkyl), S(O)(C_{1-4} alkyl), $S(O)_2$(C_{1-4} alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)$_2$, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)$_2$, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), CF_3 or OCF_3;

unless otherwise stated heterocyclyl is optionally substituted by C_{1-6} alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3, OCF_3, (C_{1-4} alkyl)C(O)NH, $S(O)_2NH_2$, C_{1-4} alkylthio, S(O)(C_{1-4} alkyl) or $S(O)_2(C_{1-4}$ alkyl)} or heteroaryl {which itself optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3, (C_{1-4} alkyl)C(O)NH, $S(O)_2NH_2$, C_{1-4} alkylthio, S(O)(C_{1-4}

alkyl) or $S(O)_2(C_{1-4}$ alkyl)}], phenyl {optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3, OCF_3, (C_{1-4} alkyl)C(O)NH, $S(O)_2NH_2$, C_{1-4} alkylthio, $S(O)(C_{1-4}$ alkyl) or $S(O)_2(C_{1-4}$ alkyl)}, heteroaryl {optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, nitro, CF_3, (C_{1-4} alkyl)C(O)NH, $S(O)_2NH_2$, C_{1-4} alkylthio, $S(O)(C_{1-4}$ alkyl) or $S(O)_2(C_{1-4}$ alkyl)}, $S(O)_2NR^{40}R^{41}$, $C(O)R^{42}$, $C(O)_2(C_{1-6}$ alkyl) (such as tert-butoxycarbonyl), $C(O)_2$(phenyl(C_{1-2} alkyl)) (such as benzyloxycarbonyl), $C(O)NHR^{43}$, $S(O)_2R^{44}$, $NHS(O)_2NHR^{45}$, $NHC(O)R^{46}$, $NHC(O)NHR^{47}$ or $NHS(O)_2R^{48}$, provided none of these last four substituents is linked to a ring nitrogen;

k, l, p and q are, independently, 0, 1 or 2;

R^{20}, R^{22}, R^{24}, R^{26}, R^{27}, R^{29}, R^{31}, R^{33}, R^{37}, R^{40} and R^{51} are, independently, hydrogen or C_{1-6} alkyl;

R^{21}, R^{23}, R^{25}, R^{28}, R^{30}, R^{32}, R^{34}, R^{36}, R^{38}, R^{39}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50} and R^{52} are, independently, C_{1-6} alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{5-6} cycloalkenyl, $S(C_{1-4}$ alkyl), $S(O)(C_{1-4}$ alkyl), $S(O)_2(C_{1-4}$ alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C_{3-7} cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, $S(C_{1-4}$ alkyl), $S(O)(C_{1-4}$ alkyl), $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)$_2$, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)$_2$, CO_2H, $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3;

R^{21}, R^{23}, R^{25}, R^{28}, R^{30}, R^{34}, R^{35}, R^{36}, R^{41}, R^{42}, R^{43}, R^{45}, R^{46}, R^{47} and R^{52} may additionally be hydrogen;

or a pharmaceutically acceptable salt thereof or a solvate thereof.

2. (Original) A compound as claimed in claim 1 wherein A is absent.

3. (Currently amended) A compound as claimed in claim 1 ~~or 2~~ wherein n is 1 or 2.

4. (Currently amended) A compound as claimed in claim 1~~, 2 or 3~~ wherein R^3 is hydrogen.

5. (Currently amended) A compound as claimed in claim 1~~, 2, 3 or 4~~ wherein R^1 is $NR^{13}C(O)R^{14}$~~; wherein R^{13} and R^{14} are as defined in claim 1~~.

6. (Currently amended) A compound as claimed in claim 1~~, 2, 3 or 4~~ wherein R^1 is optionally substituted aryl or optionally substituted heteroaryl~~, wherein the optional substituents are as recited in claim 1~~.

7. (Currently amended) A compound as claimed in claim 1~~, 2, 3 or 4~~ wherein R^1 is optionally substituted heterocyclyl.

8. (Currently amended) A compound as claimed in ~~any one of the preceding claims~~ claim 1 wherein R^2 is phenyl optionally substituted by halo or CF_3.

9. (Currently amended) A compound as claimed in ~~any one of the preceding claims~~ claim 1 wherein X is $NR^6S(O)_2R^7$~~; wherein R^6 and R^7 are as defined in claim 1~~.

10. (Currently amended) A compound as claimed in ~~any one of the preceding claims~~ claim 1 wherein X is $S(O)_2NR^4R^5$~~; wherein R^4 and R^5 are as defined in claim 1~~.

11. (Original) A process for preparing a compound as claimed in claim 1, the process comprising:

a. when R^1 is an N-linked optionally substituted heterocycle, reacting a compound of formula (II):



(II)

wherein R^2, R^3, n, A and X are as defined in claim 1, with a compound R^1H (wherein the H is on a heterocycle ring nitrogen atom) wherein R^1 is as defined above, in the presence of a suitable base, in a suitable solvent and optionally in the presence of sodium iodide;

b. when R^3 is hydrogen, coupling a compound of formula (III):



(III)

wherein n, A and X are as defined in claim 1, with a compound of formula (IV):



(IV)

wherein R^1 and R^2 are as defined in claim 1, in the presence of $NaBH(OAc)_3$ in a suitable solvent at room temperature;

c. when R^3 is hydrogen, coupling a compound of formula (III):



(III)

wherein n, A and X are as defined in claim 1, with a compound of formula (V):



(V)

wherein R^1 and R^2 are as defined in claim 1 and L is a leaving group; in the presence of a base, in a suitable solvent at a temperature from 60°C up to the boiling point of the solvent;

d. when X is $S(O)_2NR^4R^5$, reacting a compound:



wherein R^1, R^2, R^3, A and n are as defined in claim 1, with NHR^4R^5, wherein R^4 and R^5 are as defined in claim 1, in the presence of a suitable base and in the presence of a suitable solvent; or,

e. when X is $NR^6S(O)_2NR^7$, reacting a compound:



wherein R^1, R^2, R^3, A and n are as defined in claim 1, with $R^7S(O)_2Cl$, in the presence of a suitable base and in the presence of a suitable solvent.

12. (Original) A pharmaceutical composition which comprises a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.

13-14. (Cancelled)

15. (Original) A method of treating a CCR5 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof.